Resolian Welcomes New Leadership Team
Resolian is embarking on an exciting new chapter with a fresh leadership team that promises to enhance operations and support its clients' evolving needs. This change aims to position the company for growth on a global scale, reinforcing its commitment to delivering exceptional bioanalytical services.
Leadership Changes Announced
As part of the reorganization, Rob Stachlewitz has been appointed as the Chief Executive Officer (CEO). Meanwhile, the former CEO, Pat Bennett, will take on a new role as Chief Business Officer and President of Scientific Affairs. Additionally, Honggang Bi has been appointed as Chairman of the Board.
Expanding Global Operations
Resolian is a well-known global partner in bioanalytical and analytical sciences, specifically aiding in drug development and multi-regional clinical trials. With support from Ampersand Capital Partners and KKR's strategic growth initiatives, the company has grown rapidly in recent years. This has led to acquisitions and the establishment of high-tech laboratories. Notably, Resolian has added Alliance Pharma, and Drug Development Solutions, while also opening a new bioanalytical lab in Brisbane, which exemplifies its expanding global footprint.
Focus on Strategic Growth
Rob Stachlewitz comes to Resolian with extensive experience, having previously served as Corporate Vice President and General Manager at Charles River. His background spans over 15 years in pharmaceutical R&D, holding significant roles at companies like Boehringer Ingelheim and Abbott Laboratories. His leadership is expected to guide Resolian towards strategic growth and operational excellence.
A Visionary Leader
Chairman Honggang Bi expressed enthusiasm regarding his new role, stating his eagerness to work alongside the new CEO, Rob Stachlewitz, and the devoted team at Resolian. With over 30 years of leadership experience in drug development operations, Bi's vision aligns perfectly with the company's goals. His leadership is anticipated to elevate Resolian’s innovative approach within the bioanalytical landscape.
Pat Bennett’s New Role
As Pat Bennett transitions to his role as Chief Business Officer and President of Scientific Affairs, he will leverage his vast experience to enhance customer relationships and develop new service capabilities. During his nearly three years as CEO, he has navigated the company through transformative periods, enhancing operations and driving expansion.
Commitment to Quality and Compliance
Resolian is dedicated to maintaining high-quality standards and regulatory compliance throughout drug development processes. With nearly 500 professionals across the US, UK, and Australia, the firm is well-positioned to provide clients with leading services in GxP and nonregulated bioanalysis, drug metabolism, and GMP CMC analytical capabilities.
The Future of Resolian
Looking ahead, the combination of Honggang Bi, Rob Stachlewitz, and Pat Bennett promises a robust leadership trio that is prepared to tackle the challenges of the bioanalytical CRO industry. Their comprehensive experience forms a solid foundation to amplify Resolian's operational capabilities and bolster its global initiatives, providing top-tier support for clients worldwide.
About Resolian
Resolian (formerly known as Alliance Pharma Inc. and Drug Development Solutions) is a premier global research laboratory specializing in a range of analytical services in the biotech and pharmaceutical sectors. Boasting advanced facilities and skilled professionals, Resolian is equipped to meet the complex demands of preclinical and clinical programs at every scale while prioritizing regulatory compliance.
Frequently Asked Questions
What recent leadership changes were announced at Resolian?
Recently, Rob Stachlewitz was appointed as CEO, Pat Bennett became Chief Business Officer, and Honggang Bi was appointed Chairman.
Why is the leadership transition significant for Resolian?
This transition aims to enhance operational capabilities and support the company's expansion into new global markets.
What is Resolian's primary focus as a company?
Resolion focuses on providing specialized bioanalytical services in drug development and clinical trials, ensuring compliance and quality.
What new services does Pat Bennett plan to develop in his new role?
He aims to enhance customer relationships and grow new service capabilities, focusing on client collaboration.
How does Resolian ensure regulatory compliance?
The company maintains high standards through a team of experts and advanced technologies across its research facilities.
